CTNM — Contineum Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $501.80m
- $238.90m
Annual cashflow statement for Contineum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -29 | -24.3 | 22.7 | -42.3 | -60 |
| Depreciation | |||||
| Non-Cash Items | 2.3 | 5.07 | -2.54 | 3.82 | 10.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.108 | -1.27 | -1.02 | 5.33 | -6.04 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -26.3 | -20.1 | 19.3 | -32.8 | -55.3 |
| Capital Expenditures | -0.168 | -0.118 | -0.414 | -0.514 | -0.231 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -64.8 | 22.4 | -65.2 | -69.2 | -3.48 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -65 | 22.3 | -65.6 | -69.7 | -3.71 |
| Financing Cash Flow Items | 0.096 | -0.004 | -0.371 | 0 | 93 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 79.8 | -1.24 | 56.2 | 109 | 113 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.4 | 0.939 | 9.96 | 6.42 | 53.7 |